Patents by Inventor Randal J. Schoepp

Randal J. Schoepp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for normalizing background effects in multiplex immunoassays
    Patent number: 10379122
    Abstract: Disclosed herein methods, compositions, and kits for obtaining a normalized measured amount of a target in a sample by measuring the amount of the target in the sample by contacting the sample with a detection reagent, measuring the amount of a ligand known to be absent in the sample being tested by contacting the sample with a control reagent, and obtaining the normalized measured amount of the target by calculating the ratio of the measured amount of the target to the measured amount of the ligand.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: August 13, 2019
    Inventors: Neal G. Satterly, Randal J. Schoepp
  • Virus-like Particle Bound Magnetic Particles as Reagents for Immunodiagnostics
    Publication number: 20190178881
    Abstract: Described herein are virus-like particles (VLPs) that were generated to present the viral glycoprotein antigens on their surface, coupled to magnetic fluorescent microspheres to create VLP-conjugated microspheres (VCMs) and methods of making them. These VCMs were stable when lyophilized and stored at 37° C. and able to detect antibodies in non-human primate (NHP) and human clinical sera at dilutions of 1×105 and 1×104, respectively. Methods are also disclosed for detecting an immune response using VCMs.
    Type: Application
    Filed: November 2, 2018
    Publication date: June 13, 2019
    Inventors: Keersten M. Ricks, Charles J. Shoemaker, Randal J. Schoepp, Connie S. Schmaljohn
  • Recombinant chimeric human anti-botulinum antibodies
    Patent number: 7563875
    Abstract: In this application is described the production of recombinant, chimeric, humanized antibodies specific for both BoNt/A and BoNT/B. The humanized antibodies were converted from a mouse anti-BoNT/A/B Fab fragment into a whole human IgG1 antibody. The antibodies are useful in assays for detecting human exposure to BoNT/A and BoNT/B.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: July 21, 2009
    Assignee: The United States of America as represented by the Sercretary of the Army
    Inventors: Thomas J. Palys, Randal J. Schoepp, Kara E. Schmid